首页> 外文期刊>Journal of Clinical Pathology >Limitations in the ability of NB84 to detect metastatic neuroblastoma cells in bone marrow.
【24h】

Limitations in the ability of NB84 to detect metastatic neuroblastoma cells in bone marrow.

机译:NB84检测骨髓中转移性神经母细胞瘤细胞的能力有限。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: The accurate assessment of metastases is an essential component of the staging process for children with neuroblastoma. AIMS: To study the sensitivity of the immunohistochemical marker neuroblastoma 84 (NB84) for the detection of bone marrow infiltrates in children with stage 4 neuroblastoma. METHODS: Primary tumour specimens, bone marrow trephine biopsy specimens and lymph node metastases, taken from children with neuroblastoma that had metastasised to bone marrow, were assessed with a panel of commonly used immunohistochemical markers for neuroblastoma. A comparison was drawn between the sensitivity of the marker NB84 for primary tumours and for bone marrow metastases. RESULTS: NB84 immunolabelled all pre-chemotherapy and post-chemotherapy (n = 24) paired primary tumour specimens, as well as each of a further 20, unpaired, pre-chemotherapy primary tumour specimens. It also labelled all (n = 4) lymph node metastases. Immunolabelling of bone marrow trephine biopsy specimens (21/33) was lesssensitive. Of 16 primary tumour specimens with a paired bone marrow trephine biopsy specimen, all immunostained positive, whereas only 62.5% of bone marrow biopsy specimens immunostained positive for NB84. The number of bone marrow biopsy specimens immunostaining for NB84 was significantly lower than the number of paired primary tumour specimens (p = 0.041). CONCLUSIONS: NB84 remains a useful marker for the diagnosis of neuroblastoma in primary tumour specimens, but not for neuroblastoma that has metastasised to bone marrow.
机译:背景:准确评估转移灶是儿童神经母细胞瘤分期过程的重要组成部分。目的:研究免疫组化标记物神经母细胞瘤84(NB84)对4期神经母细胞瘤患儿骨髓浸润的检测敏感性。方法:使用一组常用的神经母细胞瘤免疫组织化学标记物评估从原发于骨髓的神经母细胞瘤患儿的原发性肿瘤标本,骨髓环冰活检标本和淋巴结转移。比较了标记物NB84对原发肿瘤和骨髓转移瘤的敏感性。结果:NB84免疫标记了所有化疗前和化疗后(n = 24)配对的原发肿瘤标本,以及另外20个未配对的化疗前原发肿瘤标本。它还标记了所有(n = 4)淋巴结转移。骨髓环冰活检标本的免疫标记(21/33)敏感性较低。在16例原发性肿瘤标本中有配对的骨髓冰毒活检标本中,所有免疫染色均呈阳性,而仅NB.84的骨髓活检标本中有62.5%免疫染色呈阳性。 NB84免疫染色的骨髓活检标本数量显着低于配对的原发肿瘤标本数量(p = 0.041)。结论:NB84仍然是诊断原发性肿瘤标本中神经母细胞瘤的有用标志物,但不适用于转移到骨髓的神经母细胞瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号